valproic acid has been researched along with Leukemia, Myeloid, Acute, M4 in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A particular VPA/ATRA responsiveness of Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (ALL) was confirmed in a therapy-refractory patient in vivo." | 1.33 | FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. ( Barth, PJ; Burchert, A; Cai, D; Neubauer, A; Ottmann, OG; Wang, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fredly, H | 1 |
| Reikvam, H | 1 |
| Gjertsen, BT | 1 |
| Bruserud, O | 1 |
| Cai, D | 1 |
| Wang, Y | 1 |
| Ottmann, OG | 1 |
| Barth, PJ | 1 |
| Neubauer, A | 1 |
| Burchert, A | 1 |
1 trial available for valproic acid and Leukemia, Myeloid, Acute, M4
| Article | Year |
|---|---|
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarab | 2012 |
1 other study available for valproic acid and Leukemia, Myeloid, Acute, M4
| Article | Year |
|---|---|
FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Transformation, Neoplastic; Drug Resistance, Neopla | 2006 |